A Comparative Study of Different Presentation Strategies for an HIV Peptide Immunogen

Bioconjugate Chemistry

Volumn 15, Issue 1, 2004, Pages 112-120

  Cruz, Luis J ^a   Iglesias, Enrique ^b   Aguilar, Julio C ^b   González, Luis J ^b   Reyes, Osvaldo ^b   Albericio, Fernando ^a,c   Andreu, David ^d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DENDRIMERS; DEXTRAN; EPITOPES; VACCINES;

AMINO-ACIDS; ANTIGENICS; B CELLS; CELL EPITOPES; COMPARATIVES STUDIES; CROSS-REACTIVITY; IMMUNOGENICITY; IMMUNOGENS; PRESENTATION STRATEGIES; TETANUS TOXOID;

PEPTIDES;

CARRIER PROTEIN; DENDRIMER; DEXTRAN; EPITOPE; HEPATITIS B SURFACE ANTIGEN; MULTIPLE ANTIGEN PEPTIDE; PEPTIDE LGQALY; PEPTIDE LXQXLY; PEPTIDE LXQXXY; SYNTHETIC PEPTIDE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOLESCENT; AMINO ACID SEQUENCE; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CONJUGATION; CROSS REACTION; EPITOPE MAPPING; FEMALE; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; IMMUNOGENICITY; MACROMOLECULE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OLIGOMERIZATION; PEPTIDE SYNTHESIS; SPOT SYNTHESIS TECHNIQUE; TECHNIQUE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

EID: 0842285213     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc034119j     Document Type: Article

References (43)

1. Tam, J. P. (1988) Synthetic peptide vaccine design: synthetic and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U.S.A. 85, 5409-5413.
2. Tomalia, D. A., Baker, H., Dewald, J., Hall, M., Kallos, G., and Martin, S (1985) A new class of polymers: Starburstdendritic macromolecules. Polym. J. 17, 117-132.
3. 22 virus strain. Vaccine 14, 1375-1380.
4. BenMohamed, L., Wechsler, S. L., and Nesburn, A. B. (2002) Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis. 2, 425-431.
5. Lindner, W., and Robey, F. A. (1987) Automated synthesis and use of N- chloroacetyl-modified peptides for the preparation of synthetic peptide polymers and peptide-protein immunogens. Int J Pept. Protein Res. 30, 794-800.
6. Borras-Cuest, F., Fedon, Y., and Pellit-Camordan, A. (1988) Enhancement of peptide immunogenicity by linear polymerization. Eur J Immunol. 18, 199-202.
7. Defoort, J. P., Nardelli, B., Huang, W., and Tam, J. P. (1992) A rational designo f synthetic peptide vaccine wiht a built-in adjuvant. A modular approach for unambiguity. Int. J. Pept. Protein Res. 40, 214-221.
8. Singh, M., Li, X. M., Wang, H., McGee, J. P., Zamb, T., Koff, W., Wang, C. Y., and O'Hagan, D. T. (1998) Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine 16, 346-352.
9. Gregoriadis, G. (1994) Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment. Immunomethods 4, 210-216.
10. Lovgren, K., and Larsson, M. (1994) Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate. J. Immunol. Methods 173, 237-243.
11. Cruz, L. J., Iglesias, E., Aguilar, J. C., Quintana, D., Garay, H. E., Duarte, C., and Reyes, O. (2001) Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J. Pept. Sci. 7, 511-518.
12. Moore, J. P., and Nara, P. L., (1991) The role of the V3 loop in HIV infection. AIDS 5, 521-533.
13. Nara, P. L., Garrity, R. R., and Goudsmit, J. (1991) Neutralization of HIV-1: a paradox of humoral properties. FASEB J. 5, 2437-2455.
14. Speck, R. F., Wehrly, K., Platt, E. J., Atchison, R. E., Charo, I. F., and Kabat, D. (1997) Selctive employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J. Virol. 71, 7136-7139.
15. Berzofsky, J. A. (1991) Development of artificial vaccines against HIV using defined epitopes. FASEB J. 5, 2412-2418.
16. Schreiber, M., Wachsmuth, C., Muller, H., Hagen, C., Schmitz, H., and Van-Lunzen, J. (1996) Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. J. Gen. Virol. 77, 2403-2414.
17. Rubinstein, A., Goldstein, H., Pettoello-Mantovani, M., Mizrachi, Y., Bloom, B. R., Furer, E., Althaus, B., Que, J. U., Hasler, T., and Cryz, S. J. (1995) Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 9, 243-251.
18. Letvin, N. L., Robinson, S., Rohne, D., Axthelm, M. K., Fanton, J. W., Bilska, M., Palker, T. J., Liao, H. X., Haynes, B. F., and Montefiori, D. C. (2001) Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol. 75, 4165-4175.
19. Yamanaka, T., Fujimura, Y., Ishimoto, S., Yoshioka, A., Konishi, M., Naritam, N., Mimaya, J., Meguro, T., Nakasone, T., Okamoto, Y., Yoshizaki, H., Yamada, K., and Honda, M. (1997) Correlation of titer of antibody to principal neutralizing domain of HIVMN strain with disease progression in Japanese hemophiliacs seropositive for HIV type 1. AIDS Res. Hum. Retroviruses 4, 317-326.
20. Esparza, J., Osmanov, S., and Heyward, W. I. (1995) HIV Preventive Vaccines. Progress to date. Drugs 50, 792-804.
21. Yourno, J., Josephs, S. F., Reitz, M., Zagury, D., F., Wong-Staal, R., and Gallo, C. (1988) Nucleotide sequences analysis of the env gene of a new Zairian isolate of HIV-1. AIDS Res. Hum. Retroviruses 4, 165-173.
22. Panina-Bordingnon, P., Tan, G., Termijtelen, A., Demotz, S., Corradin, G., and Lanzavecchia, A. (1989) Universally immunogenic T-cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T-cells. Eur. J. Immunol. 19, 2237-2247.
23. Houghten, R. A., Graw, S. T., and Bray, M. K., (1986) Simultaneous multiple peptide synthesis: The rapid preparation of large numbers of discrete peptides for biological, immunological and methodological studies. BioTechniques 4, 522-526.
24. Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. (1970) Color test for detection of free terminal amino groups in solid-phase synthesis of peptides. Anal.Biochem. 34, 595-598.
25. Houghten, R. A., Bray, M. K., Degraw, S. T., and Kirby, C. J. (1986) Simplified procedure for carrying out simultaneous multiple hydrogen fluoride cleavages of peptides resins. Int. J. Pept. Protein Res. 27, 673-678.
26. Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70-77.
27. Fields, G. B., and Noble, R., L. (1990) Solid-phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35, 161-214.
28. Krchnak, V., Maly, A., and Flegel, M. (1988) Solid-phase synthesis of a nonadecapeptide coded for by the v-myb oncogene. Int. J. Pept. Protein Res. 2, 239-244.
29. Deen, C., Claassen, E., Gerritse, K., Zegers, N. D., and Boersma, W. J. A. (1990) A novel carbodiimide coupling method for synthetic peptides: Enhanced antipeptide antibody responses. J. Immunol. Methods 129, 119-125.
30. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
31. Gonzalez, J., Besada, V., Garay, H., Reyes, O., Padron, G., Tambara, Y., Takao, T., and Shimonishi, Y. (1996) Effect of the position of a basic amino acid on C-terminal rearrangement of protonated peptides upon collision-induced dissociation. J. Mass. Spectrom. 31, 150-158.
32. Mo, W., Sakamoto, H., Nishikawa, A., Kagi, N., Langridge, J. I., Shimonishi Y., and Takao, T. (1999) Structural characterization of chemically derivatized oligosaccharides by nanoflow electrospray ionization mass spectrometry. Anal. Chem. 71, 4100-4106.
33. Gómez, C. E., López-Campistrous, A. E., and Duarte, C. A. (1998) An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 + Human sera. J. Virol. Methods 71, 7-16.
34. Frank, R. (1992) Spot-Synthesis: An easy technique for the positionally addressable, parllel chemical synthesis on a membrane support. Tetrahedron 48, 9217-9232.
35. Hardy, E., Martinez, E., Diago, D., Diaz, R., Gonzalez, D., and Herrera, L. (2000)Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. J. Biotechnol. 77, 157-167.
36. Cruz, L. J., Quintana, D., Iglesias, E., Garcia, Y., Huerta, V., Garay, H. E., Duarte, C., and Reyes, O. (2000) Immunogenicity Comparison of a Multi-antigenic Peptide Bearing V3 Sequences of the Human Immunodeficiency Virus Type 1 with TAB9 Protein in Mice. J. Pept. Sci. 6, 217-224.
37. Chai, S. K., Clavijo, P., Tam, J. P., and Zavala, F. (1992) Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J. Immunol. 149, 2385-2390.
38. McLean, G. W., Owsianka, A. M., Subak-Sharpe, J. H., and Marsden, H. S. (1991) Generation of anti-peptide and antiprotein sera. Effect of peptide presentation on immunogenicity. J. Immunol. Methods 137, 149-157.
39. Kanda, P., Fritz, D. A., Gage, D. A., and Shuler, K. R. (1995) Dependence of the murine antibody response to an anti-CDR2 VH peptide on immunogen formulation. Mol. Immunol. 32, 1319-1328.
40. Helling, F., and Livingston, P. O. (1994) Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol. Chem. Neuropathol. 21, 299-309.
41. Wang, C. Y, Looney, D. J, Li, M. L., Walfield, A. M., Ye, J., Hosein, B., Tam, J. P., and Wong-Staal, F. (1991) Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 254, 285-288.
42. Zhang, P. F., Bouma, P., Park, E. J., Margolick, J. B., Robinson, J. E., Zolla-Pazner, S., Flora, M. N., and Quinnan, G. V. (2002)Peng Fei Zhang. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76, 644-655.
43. Diwan, M., Misra, A., Khar R. K., and Talwar, G. P. (1997) Long-term high immune response to diphtheria toxoid in rodents with diphtheria toxoid conjugated to dextran as a single contact point delivery system. Vaccine 15, 1867-1871.